NCT05348811 2026-01-06
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
Phase 2 Completed
Clinical Trials
6 trialsNCT05010681 2025-02-27
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Fudan University
Phase 2 Recruiting
NCT05010668 2025-02-21
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2 Completed
NCT05913661 2023-06-22
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05251662 2022-02-23
Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05207735 2022-01-26
SCRCA
Henan Cancer Hospital
Phase 2 Unknown